Elvitegravir

Medical Advocates
Elvitegravir/Tenofovir/Emtricitabine/Cobicistat (Stribild)

Conference Citations

Stribild Main Page

Main New/Newsworthy

Home Page

Last Update: July 30, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

XX International AIDS Conference

Safety, efficacy and pharmacokinetics of the once-daily integrase inhibitor -based stribild single-tablet regimen in HIV-infected treatment-naīve adolescents through 24 weeks of treatment
K. Chokephaibulkit, A. Gaur, J. Fourie, et al
Abstract

Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV patients with renal impairment
J. Szwarcberg, J.F. Andrade-Villanueva, M. Fisher, et al
Abstract

Week 144 renal safety of Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) from two phase 3 randomized controlled trials
C. Cohen, F. Post, J. Winston, et al
Abstract

Safety analysis of switching to STB from a RTV-boosted PI or NNRTI Plus TVD regimen
A. Mills, B. Wade, J. Arribas, et al
Abstract

Stribild Main Page

Main New/Newsworthy

Home Page

Elvitegravir/Tenofovir/Emtricitabine/Cobicistat Conference Citations